All In Biotech

Drug Trial Radar · NCT05609370

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

113

Actual

Start

Jan 29, 2023

Primary completion

May 23, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.

Conditions

  • Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Interventions

  • AlcestobartDrug

    Administered intravenously (IV) at one of the following doses * Low dose: 150 mg once every 3 weeks * Medium dose: 300 mg once every 3 weeks or 200 mg once every 2 weeks * High dose: 600 mg once every 3 weeks or 400 mg once every 2 weeks

  • TislelizumabDrug

    Administered intravenously at a dose of either 200 mg once every 3 weeks or 300 mg once every 4 weeks.

  • Bevacizumab or Bevacizumab biosimilarDrug

    Administered intravenously at a dose of either 7.5 mg/kg once every 3 weeks or 5 mg/kg once every 2 weeks.

  • Fluoropyrimidine (FP)Drug

    Fluoropyrimidine treatment included one of the following: \- Capecitabine 850 mg/m\^2 administered orally twice daily for the first 2 weeks of each 3-week cycle, OR \- 5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment was 16.2 months.
  2. Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and CTime frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)

Locations

64 sites in 4 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology, Llc

    Anchorage, Alaska

  • Banner Md Anderson Cancer Center

    Gilbert, Arizona

  • Helios Clinical Research

    Cerritos, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Usc Norris Comprehensive Cancer Center (Nccc)

    Los Angeles, California

  • UCLA Hematologyoncology

    Los Angeles, California

  • Hoag Memorial Presbyterian

    Newport Beach, California

  • Kaiser Permanente Northern California

    Vallejo, California

  • Baptist Md Anderson Cancer Center

    Jacksonville, Florida

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • Baptist Health Lexington

    Lexington, Kentucky

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Pontchartrain Cancer Center

    Covington, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Washington University School of Medicine

    St Louis, Missouri

  • St Vincent Frontier Cancer Center

    Billings, Montana

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Cancer Care Specialists

    Reno, Nevada

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • Perlmutter Cancer Center At Winthrop Oncology Hematology Associatesnyu Winthrop Hospital

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Duke Cancer Center

    Durham, North Carolina

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Ut Southwestern Medical Center

    Dallas, Texas

  • Ut Health San Antonio Mays Cancer Center

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Cancer Care Northwest

    Spokane Valley, Washington

  • Multicare Health System Institute For Research and Innovation

    Tacoma, Washington

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

  • Orange Health Service (Central West Cancer Care Centre)

    Orange, New South Wales, Australia

  • Riverina Cancer Care Centre

    Wagga Wagga, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • St John of God, Murdoch

    Murdoch, Western Australia, Australia

  • One Clinical Research

    Nedlands, Western Australia, Australia

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.